(Q57628889)

cost-effectiveness analysis

inferred from title

1 reference

acute myocardial infarction

inferred from title

1 reference

Aldo Pietro Maggioni

2

0 references

author name string

Maria Grazia Franzosi

1

0 references

Eugenio Santoro

3

0 references

Gianni Tognoni

4

0 references

Emanuele Cavalieri

https://scigraph.springernature.com/pub.10.2165/00019053-199813030-00008

5

0 references

publication date

1998

0 references

published in

PharmacoEconomics

0 references

volume

13

0 references

issue

3

0 references

page(s)

337-346

0 references

exact match

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.

1 reference

12 December 2020

Is the use of t-PA as compared with streptokinase cost effective?

1 reference

12 December 2020

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

1 reference

12 December 2020

Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction.

1 reference

12 December 2020

A clinician's guide to cost-effectiveness analysis

1 reference

12 December 2020

The clinical-economic trial: promise, problems, and challenges

1 reference

12 December 2020

Cost-effectiveness analysis: are the outputs worth the inputs?

1 reference

12 December 2020

Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Mio

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

12 December 2020

Economic analysis and clinical trials

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin

1 reference

12 December 2020

GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction

1 reference

12 December 2020

Economic analysis in randomized control trials

1 reference

12 December 2020

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor

1 reference

12 December 2020

Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1)

1 reference

12 December 2020

ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials.

1 reference

12 December 2020

Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis

1 reference

12 December 2020

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

1 reference

12 December 2020

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

12 December 2020

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

12 December 2020